Next Generation Cancer Diagnostics: Technologies and Global Markets

Next Generation Cancer Diagnostics: Technologies and Global Markets

  • August 2020 •
  • 318 pages •
  • Report ID: 2354691 •
  • Format: PDF
Report Scope:
The scope of this report includes next generation diagnostic technologies, applications, industry subsegments, major funding initiatives, patents and companies. The market sizes for next generation cancer diagnostics are given for 2019, 2020 (estimated) and 2025 (forecasted).

This report reviews the main next generation diagnostic technologies, including next generation sequencing (NGS), polymerase chain reaction (PCR), multiplex conventional, cell or extracellular vesicle capture and arrays/microfluidics. The report also discusses, in-depth, various liquid biopsy platforms and how these compare with tissue-based testing.

The report discusses several significant, large-scale research initiatives that contribute to cancer diagnostic development. Key forces driving the market are enumerated.

The structures of several important industry subsectors are reviewed, as well as major industry acquisitions and strategic alliances from Jan. 2019 through June 2020. The industry subsectors analyzed include DNA sequencing instruments, long-read DNA sequencing, informatics, PCR, droplet digital PCR, CTC capture and detection and liquid biopsy.

The market for next generation cancer diagnostics is analyzed in depth. The market is analyzed by cancer site (bladder, brain, breast, colorectal, cancer of unknown primary, gastric, gynecologic, hematologic, kidney, liver, lung, pan-cancer, pancreatic, prostate, melanoma and thyroid), by test purpose (screening/early detection, diagnosis, monitoring, therapy guidance), by test platform (arrays/microfluidics, cell/EV capture, multiplex conventional, PCR and NGS) and by geography (North America, Europe, Asia Pacific, Rest of World).

Market data covers 2019, 2020 (estimated) and 2025 (forecasted).

There is a special section discussing the impact of COVID-19 on the market for next generation cancer diagnostics.

More than 130 companies in the next generation cancer diagnostics industry are profiled in this report.

The analyst provides a summary of the main industry acquisitions and strategic alliances from Jan. 2019 through June 2020, including key alliance trends.

Report Includes:
- 22 data tables and 74 additional tables
- An overview of the global market and technologies for next generation cancer diagnostics
- Analyses of global market trends, with data from 2019, estimates for 2020, and projections of compound annual growth rates (CAGRs) through 2025
- Analyses of the next generation cancer diagnostics market by cancer site, analysis purpose, analysis platform and region
- Discussion on arrays and microfluidics (LOAC) technologies, multiplex conventional technologies, next generation sequencing technology and polymerase chain reaction (PCR) technology
- Evaluation of current market trends, market size, market forecast, pipeline analysis of new products, and regulatory scenarios of the cancer diagnostics market
- Discussion on factors affecting the market including cancer diagnostics needs, regulatory trends, industry structure, and patent statuses
- Details of the key initiatives and programs related to the next generation cancer diagnostics market
- Market share analysis of the key companies of the industry, their strategic profiling, competitive landscape, and their detailed company profiles, including Abbott Laboratories, Illumina Inc., Myriad Genetics Inc., Qiagen NV, Oche Holding AG, and Thermo Fisher Scientific Inc.

Summary:
Advanced diagnostics for cancer represent a major market opportunity for life sciences companies.Many cancer types are on the rise as the aging populations of many countries continue to grow.

As a result, there is an increasing demand for noninvasive, diagnostic assays that can detect cancers earlier, molecularly subtype tumors to guide therapy decisions and monitor cancer recurrence in treated individuals.

Despite advances in treatment, cancer remains the second leading cause of death, worldwide.Cancer exerts a tremendous toll on patients, families and society as a whole.

One pressing need in cancer diagnostics is earlier stage identification, identifying cancer before it has spread to other parts of body.In order to meet this need, a number of companies are using advanced diagnostic platforms to develop and validate assays that detect cancer earlier.

Sanomics, Prenetics, Guardant, Thrive Earlier Detection, AnPac BioMedical and Grail are notable examples.

A second pressing need in cancer is more accurate classification of suspicious lesions or nodules (malignant or benign).Accurate classification leads to better treatment decisions and fewer unnecessary, invasive biopsies.

In the case of lung cancer, peripheral lung nodules are very difficult to biopsy, deep within the small branches of the lung, often beyond the reach of the bronchoscope.Needle biopsy is problematic, carrying the risk of lung collapse and/or infection.

New, non-invasive blood-based tests are needed to assess nodules.

A third, important medical need is for cancer diagnostics that guide therapy decisions.These diagnostics can be used to assess a patient’s likely response to a particular therapy, providing the physician with a guide to subsequent treatments.

This is a growing application for both tissue and liquid-based assays.

These assays establish which of the newer, targeted drugs, including those that block certain molecular pathways, will work most effectively for a given tumor. This convergence of targeted drugs with genomics-based diagnostics leads to a powerful new paradigm in medicine.